Trial Profile
Phase I Study of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Mature T-Cell Non-Hodgkin Lymphoma: the aTAC BEAM Regimen
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Basiliximab Y-90 (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
- Indications Cutaneous T-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions
- 18 Mar 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 17 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 17 Mar 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.